Sanyou Bio funding, valuation and investors

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. is a Shanghai-founded (2015) antibody discovery and preclinical development business that serves biotech, pharmaceutical and diagnostic developers. On November 9, 2026 its issuer-issued PR Newswire statement announced a completed Series C exclusively funded by Zero2IPO Industry Investment, managed by Zero2IPO Group.

The issuer described the amount with a 'nearly' qualifier; at the European Central Bank November 9 reference rate this is less than approximately $15 million in USD, NOT an exact $15 million round. The company also describes lifetime funding of less than approximately $45 million at the same reference rate, which is cumulative across rounds and should never be counted as Series C proceeds.

The legal close date and valuation are not disclosed. Sources: https://www.prnewswire.com/news-releases/sanyou-bio-secures-exclusive-series-c-investment-from-zero2ipo-industry-investment-bringing-total-funding-to-nearly-rmb-300-million-302932833.html and https://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/html/index.eu.html .

Sanyou's AI-STAL product is an antibody and molecular library from which candidate molecules can be selected and screened against a customer's therapeutic target. SAI-DA combines computational molecule design and prioritization with real wet-lab work such as antibody generation, in-vitro functionality, in-vivo evaluation, engineering, developability screening, cell-line development and pilot manufacturing.

Clicklinks, publicly launched in August 2026, is a collaboration program rather than a proven self-service marketplace: partnership models include research services, co-development, joint investments and NewCos. Company site: https://www.sanyoubio.com/ ; product launch: https://www.prnewswire.com/news-releases/clicklinks--sanyou-bio-launches-clicklinks-an-ai-driven-innovation-hub-for-original-drug-discovery-302862406.html .

Illustrative customer workflow, NOT hands-on testing: a biotech supplies an antigen/target and success criteria; Sanyou selects and screens library candidates with AI-assisted methods; scientists express/test antibody leads in vitro; promising molecules are engineered and tested for specificity, stability and functional activity; selected leads undergo developability and possibly animal-model work; validated preclinical candidate packages are handed over for IND-enabling studies or codevelopment.

Actual assay protocols, timelines, ownership of intellectual property, milestone economics and pricing vary by contract and are not publicly disclosed. The company describes more than 3,000 historical projects and laboratory capacity exceeding 20,000 square metres, and reports partnerships with pharma companies internationally.

Project counts and partnerships are neither numbers of paying customers nor proof that any specific candidate has gained marketing approval. Partner clinical progress and regulatory filings are not the same as Sanyou-owned FDA-approved therapies.

Its announced September 2026 dual-payload ADC collaboration with NovoCodex demonstrates planned research cooperation, not clinical validation: https://www.prnewswire.com/news-releases/strategic-collaboration--sanyou-bio-and-novocodex-partner-to-co-develop-innovative-dual-payload-adcs-302888906.html .

Funding history includes a May 2020 Series A with Haier Biomedical and Shanghai Liferiver Bio-Tech; a June 26, 2021 Series B co-led by LH Ventures and Montesy Investment; and an August 2, 2022 Series B+ led by Huatai Zijin-affiliated funds. The specific USD/EUR equivalent of historical rounds cannot be reconstructed without reliable original amounts and transaction-date FX, so those amounts remain undisclosed publicly.

Historical issuer statements: https://www.prnewswire.com/news-releases/sanyou-biopharmaceuticals-completes-series-b-financing-and-secures-its-leading-role-in-innovative-antibody-drug-discovery-301320548.html and https://www.prnewswire.com/news-releases/sanyou-biopharmaceuticals-closed-the-series-b-financing-round-of-tens-of-millions-of-rmb-led-by-huatai-zijin-301598027.html .

A February 24, 2026 shareholding restructuring transferred existing holdings from Haier Financial Holdings to Liferiver Biotech and Yanghe Investment. That secondary ownership transaction is not evidence of a fresh issuer cash raise and is not added to funding totals: https://www.prnewswire.com/news-releases/sanyou-biopharmaceuticals-announces-new-strategic-investor-liferiver-biotech-increases-its-stake-and-gree-groups-yanghe-investment-joins-as-a-strategic-shareholder-302695227.html .